Vaccine
OwnerBrigitte Desiree Alberte Colau, Marguerite Deschampsinventors
Life of this patent
Estimating the term…
Abstract
The invention relates to vaccine formulation comprising a split enveloped virus preparation wherein the virus RSV or PIV, methods of preparing such formulation, and use of such formulations in prevention or treatment of disease.
Claims29
A vaccine formulation comprising a split enveloped RSV virus preparation, wherein the split enveloped virus preparation comprises viral membrane fragments, viral membrane envelope proteins, viral matrix and nucleoproteins.
A vaccine formulation as claimed in any one of the preceding claims wherein vaccine is formulated to be delivered intranasally.
A vaccine formulation as claimed in any one of the preceding claims which additionally comprises an adjuvant.
A vaccine formulation as claimed in any preceding claim which additionally comprises a carrier.
A method of producing a vaccine formulation as claimed in any one of the preceding claims which comprises the steps of
- (a) splitting an RSV enveloped virus;
- (b) optionally admixing the split enveloped virus preparation with a stabilising agent;
- and
- (c) optionally admixing the split enveloped virus preparation with an adjuvant.
Use of a split RSV vaccine preparation in the manufacture of a vaccine.
Use of a split RSV vaccine preparation in the manufacture of a vaccine formulation for the prophylaxis or treatment of disease.
Use of a split RSV vaccine preparation in the manufacture of a vaccine formulation for intranasal or intradermal delivery.
A formulation, method, use, kit, or device according to any preceding claim, wherein the vaccine formulation is immunogenic.
Dependencies are inferred from the claim text.